BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,735.3 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Total Liabilities?

BridgeBio Pharma's Total Liabilities for the quarter that ended in Mar. 2024 was €1,735.3 Mil.

BridgeBio Pharma's quarterly Total Liabilities declined from Sep. 2023 (€1,732.27 Mil) to Dec. 2023 (€1,732.14 Mil) but then increased from Dec. 2023 (€1,732.14 Mil) to Mar. 2024 (€1,735.30 Mil).

BridgeBio Pharma's annual Total Liabilities increased from Dec. 2021 (€1,662.36 Mil) to Dec. 2022 (€1,763.35 Mil) but then declined from Dec. 2022 (€1,763.35 Mil) to Dec. 2023 (€1,732.14 Mil).

BridgeBio Pharma Total Liabilities Historical Data

The historical data trend for BridgeBio Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Total Liabilities Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

140.13

489.67

1,662.36

1,763.35

1,732.14

BridgeBio Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,717.90	1,710.60	1,732.27	1,732.14	1,735.30

BridgeBio Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BridgeBio Pharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	131.905	+	(1591.646	+	8.5840000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,732.1

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	501.03	-	-1231.105
	=	1,732.1

BridgeBio Pharma's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	130.159	+	(1586.291	+	0.54700000000023
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	18.299	+	0)
	=	1,735.3

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	781.386	-	-953.909
	=	1,735.3

BridgeBio Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (FRA:2CL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma (FRA:2CL) Headlines

No Headlines